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ABSTRACT
The integrase strand transfer inhibitors (INSTIs)
are the newest antiretroviral class in the HIV
treatment armamentarium. Dolutegravir (DTG)
is the only second-generation INSTI with FDA
approval (2013). It has potential advantages in
comparison to first-generation INSTI’s,
including unboosted daily dosing, limited cross
resistance with raltegravir and elvitegravir, and a
high barrier to resistance. Clinical trials have
evaluated DTG as a 50-mg daily dose in both
treatment-naı¨ve and treatment-experienced,
INSTI-naı¨ve participants. In those treatment-
naı¨ve participants with baseline viral load
\100,000 copies/mL, DTG combined with
abacavir and lamivudine was non-inferior and
superior to fixed-dose combination
emtricitabine/tenofovir/efavirenz. DTG was
also superior to the protease inhibitor regimen
darunavir/ritonavir in treatment-naı¨ve
participants regardless of baseline viral load.
Among treatment-experienced patients naı¨ve to
INSTI, DTG (50 mg daily) demonstrated both
non-inferiority and superiority when compared
to the first-generation INSTI raltegravir (400 mg
twice daily) regardless of the background
regimen. No phenotypically significant DTG
resistance has been demonstrated in INSTI-
naı¨ve participant trials. The VIKING trials
evaluated DTG’s ability to treat persons with
HIV with prior INSTI exposure. VIKING
demonstrated twice-daily DTG was more
efficacious than daily dosing when treating
participants receiving and failing first-
generation INSTI regimens. DTG maintained
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potency against single mutations from any of the
three major INSTI pathways (Y143, H155, Q148);
however, the Q148 mutation with two or more
additional mutations significantly reduced its
potency. The long-acting formulation of DTG,
GSK1265744LA, is the next innovation in this
second-generation INSTI class, holding promise
for the future of HIV prevention and treatment.
Keywords: Antiretroviral therapy (ART);
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INTRODUCTION
The ability of HIV to rapidly mutate and
develop resistance to standard antiretroviral
therapy (ART) necessitates the ongoing drug
development of new and efficacious therapeutic
options that are well tolerated and evade prior
resistance pathways. In the last decade,
development of new antiretroviral drugs has
rapidly expanded, resulting in six ART drug
classes: nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs/NtRTIs), non-
nucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs), and newer
drug classes including fusion inhibitors (FIs),
CCR5 co-receptor antagonists (CRAs), and
integrase strand transfer inhibitors (INSTIs).
These newer drug classes provide novel
mechanisms of action, but with certain
limitations. For example, enfuvirtide, a FI,
requires twice-daily injections and maraviroc,
a CRA requires an expensive tropism assay to
determine effectiveness. The INSTIs provide
advantages in newer HIV treatment options by
offering minimal toxicity, daily dosing, and
antiviral activity against viruses resistant to
other drug classes. The objective of this review
is to provide an update and overview of DTG,
the newest generation INSTI.
OVERVIEW OF AVAILABLE
FDA-APPROVED INSTI DRUGS
Three drugs in the INSTI class are currently
approved by the FDA: raltegravir (RAL) (2007
treatment experienced only, 2009 treatment
naı¨ve approval), elvitegravir (EVG) (2012 as a
combination pill), and most recently
dolutegravir (DTG) (2013 approval for use in
treatment-naı¨ve and treatment-experienced
adolescents and adults, including those who
have been treated with other integrase strand
transfer inhibitors) (Table 1). The INSTI
mechanism of action is to prevent HIV
integrase from incorporating proviral DNA
into the human host cell, thus inhibiting the
HIV-catalyzed strand transfer step. This step has
no human homolog, making it a specific and
effective HIV drug target with excellent
tolerability and minimal toxicity.
The INSTI’s are generally metabolized by
glucuronidation by the hepatic enzyme
UGT1A1. EVG is unique among this drug class
as it is primarily metabolized by the potent
hepatic and intestinal cytochrome P450
(CYP3A4); for this reason, EVG must be
pharmacokinetically boosted with a CYP3A4
inhibitor. Cobicistat (COBI) is currently FDA
approved for this purpose in a combination
‘‘quad’’ pill: EVG/COBI/tenofovir (TDF)/
emtricitabine (FTC).
INSTI: THE FIRST GENERATION
Numerous clinical trials have investigated
optimal dosing and efficacy of the integrase
inhibitors. RAL 800 mg daily dosing is
statistically inferior (P = 0.04) to 400-mg
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twice-daily dosing when combined with the
daily fixed-dose combination of FTC/TDF [1].
The STARTMRK study (NCT00369941) of
treatment-naı¨ve participants demonstrates
that those who received daily FTC/TDF plus
RAL 400 mg twice daily have non-inferior
virologic outcomes as compared to the daily
fixed-dose combination of FTC/TDF/efavirenz
(EFV) at 48 weeks [2], 96 weeks [3], and
sustained to 156 weeks [4]. The RAL regimen
has fewer adverse events and significantly less
elevation of fasting lipids from baseline to week
144 when compared to EFV [4]. The maker of
RAL, Merck, funded these studies.
The daily fixed-dose combination EVG/
COBI/TDF/FTC is also non-inferior to FTC/
TDF/EFV at 48 weeks [5], 96 weeks [6] and
sustained to 144 weeks [7]. When tested
against the combination FTC/TDF plus a daily
protease inhibitor backbone regimen atazanavir
300 mg/ritonavir 100 mg (ATZ/r), EVG/COBI/
TDF/FTC is non-inferior at 48 weeks [8] and
96 weeks [9]. These studies support the durable
efficacy and safety profile of this INSTI daily
formulation. Gilead, the maker of EVG and the
‘‘quad’’ pill, funded these studies.
Based on these clinical trials data, RAL in
combination with FTC/TDF is a recommended
first-line therapy for starting ART [10–12]. EVG
in the form of the ‘‘quad’’ pill is also an
acceptable starting regimen for ART-naı¨ve
patients with pre-treatment creatinine
clearance [70 mL/min [10]. Monitoring
creatinine is necessary as COBI blocks the
renal tubular secretion, though with no
appreciable affect on glomerular filtration rate
(GFR).
INSTI: THE NEXT GENERATION
Dolutegravir is the latest ART agent to be FDA
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inhibitor, named for its unique properties:
unboosted daily dosing, a high barrier to
resistance, low cross-resistance to the first-
generation INSTI’s, and is now a preferred ART
regimen to initiate treatment among HIV-
infected adolescents and adults [13].
IN VITRO AND IN VIVO STUDIES
(TABLE 2)
Selecting an appropriate drug dose and
predicting the dose response requires
evaluation of both pharmacokinetics (PK) and
pharmacodynamics (PD). The in vitro protein-
adjusted half-maximal effective concentration
(PA-EC50) of DTG is 75 nM or 31.4 ng/mL [14].
The in vitro protein-adjusted half-maximal
inhibitory concentration (PA-IC50), against
HIV in peripheral blood mononuclear cells was
0.5 nM [15]. PD characteristics in vitro estimate
the protein-adjusted ninety percent inhibitor
concentration (PA-IC90) to be 0.064 lg/mL [15,
16]. In a phase 1 trial, drug concentrations
reached steady state in plasma by
approximately 5 days and half-life (t1/2)
between 13 and 15 h [15]. DTG demonstrated
excellent oral bioavailability, a moderate
elimination of half-life, and this study
maintained the drug trough concentration
well exceeding the PA-IC90 0.064 lg/mL by 5-
to 26-fold, predicting its potency as a new
antiretroviral therapeutic agent.
Understanding the correlation of dose–
response and change in HIV-1 RNA informs
optimal dosing, especially if higher doses carry
safety concerns. The PD of DTG was evaluated
in a phase 2a placebo-controlled trial among
HIV-infected, INSTI-naı¨ve participants. DTG 2,
10, or 50 mg versus placebo were randomly
assigned, and the plasma drug level and rate of
HIV RNA decline were measured [16]. The PA-
IC90 was maintained with daily dosing of 50 mg
DTG throughout a 10-day dosing interval with a
well-described exposure–response relationship,
low inter-patient variability, and predictable PK-
PD properties [16]. Potency was demonstrated
with a 2.5 log10 copies/mL mean decline in viral
load after receiving 10 consecutive days of
50 mg daily DTG as monotherapy; 70% (7/10)
had viral load \50 copies/mL by day 10 of
monotherapy which was sustained to day 14
[16].
Given these promising data, PK studies
evaluated DTG for interactions with potential
ART combinations. ATZ is a PI that is a UGT1A1
inhibitor. Concurrent dosing of ATZ 300 mg
daily or ATZ/r (300/100 mg, respectively) with
DTG was found to be safe, not requiring dose
adjustment when combined with DTG [17].
Similar studies evaluated the combination of
etravirine (200 mg twice daily), a NNRTI and a
CYP34A inducer, as well as etravirine plus the PI
combination lopinavir/ritonavir (200/400/
100 mg twice daily, respectively). Though the
CYP34A metabolic pathway of DTG is minor,
etravirine did significantly reduce the exposure
of DTG such that this combination without a
boosted PI should be avoided [18]. When co-
administered with a PI, however, the inhibitory
effect of UGT1A1 presumably counteracts the
inducement of CYP34A and no dose adjustment
is necessary with this triple ART regimen [18].
RESISTANCE
Genotypic assays identify specific mutations
that may be associated with phenotypic
resistance. DTG was specifically engineered to
deliver a novel resistance profile to avoid cross
resistance with the first-generation INSTI class
and to maintain a high barrier to resistance
[19].
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In vitro passaging experiments identify
resistance mutations by passaging virus in cell
culture in the presence of drug to select
resistance. Biochemical studies suggest INSTI’s
bind to HIV integrase in a two-step mechanism.
Mutations may alter the second step and lead to
fast INSTI dissociation kinetics that contribute
to the development of integrase resistance. In
biochemical analyses with wild-type integrase
DNA complexes, DTG demonstrated a
dissociative t1/2 of 71 h as compared to 8.8 h
for RAL and 2.7 h for EVG; thus, DTG exhibited
an off-rate 5–40 times slower than RAL and EVG
(P\0.0001) (Fig. 1) [20]. This slow dissociation
may contribute to DTG’s high barrier to
resistance and suggests that prolonged binding
plays a role in its unique resistance profile [20,
21]. Single mutations of the major RAL pathway
Y143, N155, and Q148 do not increase DTG-
fold change, and have variable effect on the off-
rate of DTG with half-lives of dissociation from
42 to 60 h for Y143 mutants, 9.6 h for N155H,
and 5.2 to 11 h for Q148 mutants. Q148 plus
additional mutations do increase the
dissociative kinetics and impart a fold change.
A fold change C3 as measured by change in
half-maximal effective concentration (EC50) of
mutant versus wild-type HIV-1 was considered
resistant for in vitro studies [19, 21]. When
mutations Q148H and G140S are present, the
dissociative t1/2 of DTG is reduced to 3.3 h [20]
with a 2.6-fold change in EC50 [19]. The VIKING
studies (discussed below; NCT01328041,
NCT00950859) demonstrate that DTG
maintains activity against RAL- and EVG-
resistant virus [22]; however, treatment-
experienced participants with Q148 ? C2
associated mutations had reduced potency
when compared to no Q148 mutations at
baseline (P\0.0001) [23]. The current FDA
label cautions that poor virologic response has
been observed in subjects with a Q148
substitution plus two or more additional
INSTI-resistance substitutions [24] (Fig. 1).
Fig. 1 INSTI pathways of HIV-1 resistance with associ-
ated dissociative t1/2 and fold change in EC50 [19]
compared to wild-type virus. Diss t1/2 dissociative values
previously reported [20, 21]. Major integrase mutations are
denoted in black bold: E92Q/V; Y143C/H/R; Q148H/K/
R; N155H. Accessory mutations are denoted in gray:
E138A/K; G140A/C/S [25]. DTG dolutegravir, EC50 half-
maximal effective concentration, EVG elvitegravir, FC fold
change, INSTI integrase strand transfer inhibitor, ND not
determined, RAL raltegravir, t1/2 half-life
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These data underpin the danger in maintaining
a failing regimen that may lead to further
accumulation of resistance mutations that can
impact the efficacy of newer drug options.
Evaluation of 3,294 genotypic resistance
tests ordered for clinical decision making from
2009 to 2012 at a United States national referral
lab revealed that integrase resistance mutations
were often paired with PI resistance [25].
Although the treatment regimen was not
available, presumably subjects included in the
database were receiving RAL based on the
timing of FDA approvals. Three major
resistance pathways reportedly lead to RAL
resistance: Y143, N155, and Q148 all of which
are in close proximity to the integrase active site
and may reduce viral fitness [25]. DTG remains
active against those with single mutations, but
accumulation of resistance mutations in the
Q148 pathway can compromise DTG activity.
Those with serial genotypic tests (n = 224) and
wild-type virus at baseline (n = 22) accumulated
INSTI mutations on average by 224 days, with
equal distribution of the three major pathways.
Overall, high-level DTG resistance was
predicted in 12% of patients with RAL- or
EVG-resistant virus (Q148 ? C2 additional
integrase mutations; the majority with
Q148 ? G140 ? E138). Thus, those failing
treatment regimens containing first-generation
INSTI should be changed early to preserve the
second-generation INSTI with high barrier to
resistance.
CLINICAL TRIALS
OF DOLUTEGRAVIR (TABLE 2)
Clinical trials of DTG have been conducted in
both treatment-naı¨ve and treatment-
experienced patients. Most clinical trials are
statistically powered for non-inferiority to
demonstrate that the new treatment is no less
effective than standard therapy. In certain
circumstances, superiority may be
demonstrated. Clinical equivalence (D) is the
largest difference that is clinically acceptable
such that a larger difference would alter clinical
practice [26]. In a non-inferiority trial, clinical
equivalence should be clearly defined such that
non-inferiority is demonstrated when the 95%
confidence interval (CI) falls entirely to the
right of the lower limit (-D). If the 95% CI of
the tested treatment effect lies both above the
lower limit of the pre-specified difference (-D)
and above zero, the trial was properly designed
and carried out in accordance with
requirements of a non-inferiority trial, and the
two-sided P value for superiority is presented
according to the intention to treat (ITT)
principle remains significant (P\0.05), then
superiority may also be claimed [26].
TRIALS AMONG ART-NAI¨VE
PARTICIPANTS
SPRING-1 (NCT00951015) is a dose-finding
study comparing the increasing daily doses of
DTG 10, 25, or 50 mg to efavirenz 600 mg with
a dual-NRTI background regimen (FTC/TDF or
abacavir (ABC)/lamivudine (3TC) in a
randomized, open-label (dose-masked) trial
[27]. Participants and investigators were not
blinded to the study drug, but were blind to
the DTG dose. Across the dosing spectrum of
DTG, the rate of viral decay was robust and
50 mg daily dosing of DTG remained
efficacious and well tolerated to 48 and
96 weeks [27, 28]. No treatment-emergent
mutations were detected [28]. Creatinine
clearance rose in week 1, gradually returning
to baseline by week 48. Lipid profile was more
favorable than with EFV with little to no
increase from baseline [27, 28].
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SPRING-2 (NCT01227824) followed as the
first trial to compare the efficacy of two INSTI’s
head to head: 400-mg twice-daily RAL versus
50-mg once-daily DTG in ART-naı¨ve patients
[29]. DTG was found to be non-inferior to RAL
at 48 weeks, regardless of NRTI background
regimen, with 88% versus 85% participants
with HIV-1 RNA \50 copies/mL. Non-
inferiority was sustained to 96 weeks (81%
versus 76%, respectively) [30]. Fewer
participants in the DTG group had protocol-
defined virologic failure (8 versus 18), and no
treatment-emergent resistance mutations were
noted in the DTG arm. Of note, virologic failure
was conservatively defined as two consecutive
viral load measures [50 copies/mL. If
participants were followed to a higher viral
load, perhaps increased levels of resistance
would have been detected; therefore lack of
emergent resistance should be interpreted with
caution [31]. Though safety in both arms was
excellent, an increase in alanine
aminotransferase (ALT) with possible drug-
induced liver injury (DILI) was noted, one case
in each study arm.
SINGLE (NCT01263015) is a randomized,
double-blinded trial, comparing DTG plus
ABC/3TC to the fixed-dose combination FTC/
TDF/EFV in a non-inferiority statistical design
[32]. The DTG arm had a rapid viral decay, with
28 days to viral suppression (\50 copies/mL)
versus 84 days in the EFV arm (P\0.0001). In
the DTG arm, 88% had HIV-1 RNA \50 copies/
mL at 48 weeks compared to 81% receiving
EFV. This result met non-inferiority criteria,
and also superiority (P = 0.003) in the ITT
analysis with the 95% CI not crossing zero.
The superior responses were primarily driven
by less discontinuation of the DTG ? ABC/3TC
regimen as compared to FTC/TDF/EFV due to
adverse events, (primarily neuropsychiatric
with EFV and insomnia with DTG) (Fig. 2).
Fig. 2 Phase 3 clinical trials of DTG and comparator
antiretroviral therapy evaluating PDVF criteria versus
discontinuation due to adverse events. PDVF deﬁned by
study endpoint ([50 copies/mL) including those who
never suppressed or those who rebounded; *FLAMINGO
study endpoint ([200 copies/mL); ?SPRING-2 study
endpoint ([50 copies/mL 9 2 from week 24–48; then up
to 200 copies/mL after week 48). DRV/r darunavir/
ritonavir, DTG dolutegravir, EFV efavirenz, PDVF proto-
col-derived virologic failure, RAL raltegravir
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Through 96 weeks, one individual receiving
DTG and three individuals receiving TDF/FTC/
EFV withdrew for insomnia. At week 96, 80%
remained suppressed (\50 copies/mL) in the
DTG ? ABC/3TC arm compared to 72% in the
TDF/FTC/EFV arm (P = 0.006; 95% CI 2.3%,
13.8%) [33]. This difference was less
pronounced for those with baseline virologic
failure [100,000 copies/mL due to withdrawals
for reasons unrelated to treatment
(DTG ? ABC/3TC = 14, TDF/FTC/EFV = 8)
(e.g., lost to follow-up, withdrawn consent,
protocol deviation) [33]. No major resistance
emerged on DTG, although a single
polymorphism of E157Q/P was noted of
uncertain significance and with no change in
phenotypic susceptibility. The lack of
resistance may reflect low-level viremia, with
20/25 (80%) participants having \200 copies/
mL at the time of virologic failure at 96 weeks
[33]. The study is continuing open label as of
week 96.
FLAMINGO (NCT01449929) is a
randomized, open-label trial comparing DTG
50 mg daily versus darunavir/ritonavir (DRV/r)
800 mg/100 mg daily [34]. At 48 weeks, 90%
receiving DTG versus 83% receiving DRV/r was
virologically suppressed. The adjusted
difference of 7.1% (95% CI 0.9–13.2%) and
P = 0.025 in ITT analysis establishes DTG as
both non-inferior and statistically superior to
DRV/r. Virologic failure ([200 copies/mL)
occurred in two participants in each study
arm, and no primary mutations were captured.
When stratified by baseline viral load, those
with HIV RNA [100,000 copies/mL (*25%)
revealed an even greater distinction with 93% of
those in the DTG arm suppressed versus 70% in
the DRV/r arm. Fewer adverse events and
withdrawals occurred in the DTG group, and
likely contributed to statistical superiority [34]
(Fig. 2).
CLINICAL TRIALS
OF DOLUTEGRAVIR IN TREATMENT
OF ART-EXPERIENCED PATIENTS
In SAILING (NCT01231516), ART-experienced,
INSTI-naı¨ve participants were randomized (1:1)
to 50-mg daily DTG or 400-mg twice-daily RAL
plus investigator-selected background therapy.
SAILING was the first and thus far only DTG
study to include resource-limited settings.
Treatment was double-blinded, active-
controlled, and designed as a non-inferiority
study with statistical superiority analysis [35].
At week 48, 71% receiving DTG versus 64%
receiving RAL demonstrated virologic
suppression \50 copies/mL, meeting non-
inferiority as well as superiority criteria [35].
Treatment-emergent resistance to the
background regimen, 3% RAL and \1% DTG,
and to INSTI, 5% RAL and 1% DTG. No
phenotypic resistance to DTG was reported.
VIKING (NCT00950859) was the first study
to evaluate DTG activity among participants
with genotypic RAL resistance in a standard
50-mg daily dose (Cohort 1) [22]. During this
study, a protocol amendment to include a
cohort receiving twice-daily 50-mg DTG was
created to compare efficacy (VIKING Cohort 2).
Twice-daily dosing was found to be more
efficacious both at day 10 (96% versus 78% for
the primary endpoint of C0.7 log10 copies/mL
change from baseline in HIV-1 RNA or \400
copies/mL) and at week 24 after optimizing the
background regimen (OBR) (75% versus 41%
with HIV-1 RNA \50 copies/mL). Those with
viral mutations including Q148H/K/R plus
G140S plus additional RAL mutations had a
reduced response to DTG.
VIKING-3 (NCT01328041) further
investigated the use of DTG in treating INSTI-
experienced participants failing their current
regimen (viral load [500 copies/mL). DTG was
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substituted for the first-generation INSTI, acting
essentially as functional monotherapy until day
8 when OBR occurred [23]. On day 8 of DTG
50 mg twice daily, the average change of HIV-1
RNA from baseline was -1.43 log10 copies/mL
(95% CI -1.52, -1.34). DTG was continued with
OBR with at least one active drug on day 8, with
69% achieving \50 copies/mL at week 24, and
63% at week 48 [36]. The presence of Q148 plus
C2 additional mutations was associated with
reduced viral decay as compared to those with no
Q148 mutation at baseline (P\0.001). Baseline
INSTI resistance (genotypic and phenotypic) and
baseline viral load were highly significant
predictors of response at week 24. For every
twofold increase in DTG change, the odds of
virologic suppression to \50 copies/mL were
63% lower, and were 96% lower if the virus
contained Q148 ?C2 mutations.
VIKING 4 (unpublished; NCT01568892) is
designed similar to VIKING 3, but with a
randomized (1:1), double-blind placebo study
design to quantitatively evaluate antiviral
activity specifically attributed to DTG [37].
Results of this study are not yet published.
PEDIATRIC FORMULATIONS
IMPAACT study P1093 (NCT01302847) is an
ongoing Phase I/II safety and dose-finding study
for treatment-experienced, INSTI-naı¨ve infants,
children and adolescents. Similar to the VIKING
studies, DTG is first added to a failing regimen
for 5–10 days, then OBR for further follow-up.
This study is composed of five age-related
cohorts ranging from [6 weeks up to 18 years.
Data for the oldest two cohorts have been
presented at scientific meetings [38–40]. The
first cohort [12 and \18 years provided data
contributing to the FDA label approving DTG
down to 12 years of age with a weight minimum
of 40 kg [24]. These pediatric studies measure
virologic suppression \400 copies/mL at
24 weeks (83%) [38] and 48 weeks (74%) with
an additional secondary endpoint as
\50 copies/mL (70% and 61%, respectively)
[39]. Virologic failure (\400 copies/mL) at
week 48 in all 6 of 23 adolescents was
attributed to incomplete adherence based on a
3-day pill recall questionnaire. There were no
DTG drug-related adverse events and no
discontinuations. The target area under the
curve at 24 h (AUC24) and concentration at
24 h (C24) were achieved with *1 mg/kg dosing
[39, 40]. A pediatric granule formulation has
been developed and tested, demonstrating that
drug exposure exceeds that of the tablet form, is
palatable, and can be given without food or
liquid restrictions [41].
ADVERSE EVENTS AND SIDE
EFFECTS
Creatinine typically rises in the first 2 weeks
after starting DTG, returning to baseline by
48 weeks [27, 29]. This rise in creatinine is
attributed to DTG’s potent inhibition of human
organic cation transporter (OCT2) that inhibits
proximal renal tubular creatinine secretion
without affecting GFR, similar to other drugs
including trimethoprim and cimetidine [42].
Approximately 1.7% of aggregate participants
in cited clinical trials experienced increased ALT
levels ([59 the normal limit) with
approximately three participants (*0.2%) with
evidence of DILI, possibly attributed to DTG
[23, 28, 29, 32, 35]. These findings have mostly
been explained by the inclusion of participants
co-infected with hepatitis B and/or hepatitis C,
who experience immune reconstitution
inflammatory syndrome (IRIS) attributed to
the potency of DTG. Overall, the most
common side effects of DTG include diarrhea,
nausea, fatigue, headaches, and insomnia.
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UNIQUE POPULATIONS
Treatment of pregnant women, and persons with
co-infections including tuberculosis, hepatitis,
or renal insufficiency can alter treatment
recommendations. While a PK study evaluating
DTG in pregnant women is underway, to date no
clinical trials have evaluated DTG use in
pregnant women, though animal studies
demonstrate that DTG can cross the placenta
[24]. The FDA label states that DTG should be
prescribed in pregnancy only if potential benefit
justifies the potential risk, category B [24]. DTG
should be given twice daily when co-
administered with rifampin (600 mg daily) as
rifampin decreases DTG exposure by
approximately 50% due to minor metabolism
via CYP3A4 [43]. Rifabutin also reduces DTG
trough concentration by about 30%, but this
reduction maintains concentrations above the
PA-IC50 (0.016 lg/mL) and does not require dose
adjustment [24, 43, 44]. Transaminase
monitoring for hepatotoxicity is recommended
when treating patients with hepatitis B and/or
hepatitis C co-infection. Those with mild-to-
moderate hepatic impairment (Child–Pugh
Score A or B) do not require dose adjustments,
but treatment in severe hepatic impairment
(Child–Pugh Score C) is not recommended.
DTG has not been studied in patients on
dialysis, and those with severe renal
impairment may have decreased drug
concentrations that could dampen therapeutic
effect and lead to resistance [24, 44, 45].
THE FUTURE
Dolutegravir is now a recommended first-line
agent in the United States for both treatment-
naı¨ve or treatment-experienced INSTI-naı¨ve
(once-daily dosing) and treatment-experienced
with suspected INI-resistance (twice-daily
dosing) adults and adolescents at least 12 years
old weighing a minimum of 40 kg [13]. In
resource-limited settings, ART is typically
limited to combination NRTI/NNRTI as first-
line regimens, and NRTI/boosted PI regimens as
second line. Third-line regimens containing
integrase inhibitors are rare, and it is unclear if
they will become available in a resource-limited
context. A fixed-dose combination of ABC/3TC/
DTG has shown bioequivalence to individual
formulations [46] and could hold promise,
especially for resource-limited settings such as
sub-Saharan Africa where the HIV burden is
high, the HLA-B*5701 mutation is rare, and
renal monitoring for regimens that include
tenofovir are limited. In 2010, ViiV Healthcare
announced the intention to make their patents,
including DTG, available to generic
manufacturers under a royalty-free agreement.
Whether these negotiations will result in the
ability of resource-limited settings to access
DTG is uncertain [47, 48]. To date, clinical
trials of DTG have primarily included white
males from developed countries. Future studies
that include more women and children, non-
subtype B virus, HIV-2 (primarily West Africa),
and non-white ethnicity are encouraged.
LONG-ACTING AGENT
GSK1265744LA
GSK1265744, a distinct integrase inhibitor from
the same chemical series as DTG, can be
formulated as a crystalline nanoparticle
suspension and is thereby amenable to
delivery as a long-acting injectable (744LA).
The 744LA formulation has unique properties
including high potency (PA-IC90 166 ng/mL),
poor water solubility (\10 lg/mL), slow
metabolism, and high melting point, allowing
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it to be formulated as a nanoparticle solution
[49, 50]. The t1/2 ranges from 21 to 50 days.
Phase I studies demonstrate that this compound
is safe and well tolerated with plasma
concentrations above the PA-IC90 for 24 weeks
or longer with doses 200 mg or greater [51].
The 744LA formulation in combination with
the long-acting rilpivirine formulation
(TMC278 LA) is being developed for use in
treatment of HIV-infected patients. This
combination holds potential promise to
expand HIV treatment options by providing
an innovative mechanism to improve
adherence, eliminate NRTI- and/or ritonavir-
related drug toxicities, and potentially enhance
drug delivery to reservoirs such as lymphoid
tissue and the central nervous system based on
preliminary data of a macrophage–carriage
system for nanoformulated crystalline ART in
experimental animal models [49, 52, 53].
The 744LA formulation is also being
developed as a single agent for pre-exposure
prophylaxis (PrEP). An animal study
challenging rhesus macaques with Simian/
Human Immunodeficiency Virus (SHIV)
recently demonstrated proof of concept of
744LA as PrEP [50]. Macaques receiving
placebo became SHIV-infected by the second
SHIV challenge on average (range 1–7); in
contrast, those receiving 744LA had no
systemic viremia for 10 weeks after the last
SHIV challenge, demonstrating a 28-fold lower
risk of infection (hazard ratio 95% CI 5.8, 136.8;
P\0.0001) [50]. A drug level three times greater
than the PA-IC90 offered 100% protection; one
to three times the PA-IC90 conferred 97%
protection, suggesting that a quarterly dose of
800 mg of 744LA might be appropriate in
humans for PrEP [50]. Phase I trials evaluating
penetration of a 400-mg dose in rectal and
cervicovaginal tissue in healthy volunteers
revealed detectable, but relatively low levels
and were slightly higher in cervicovaginal tissue
as compared with rectal tissue [54]. The amount
of drug penetration into genital tract tissues and
fluids needed to prevent infection is unknown.
SUMMARY
Dolutegravir is the latest FDA-approved
compound of the INSTI class. Its unique
properties of once-daily dosing for ART-naı¨ve
patients, lack of cross resistance to first-
generation INSTI, high genetic barrier to
resistance, and favorable safety profile welcome
DTG as the newest addition to the HIV
armamentarium in the developed world. The
clinical trials that brought DTG to market are
funded by the drug manufacturer, ViiV
Healthcare and took place primarily in well-
resourced countries. Efforts are being made to
share this costly drug with less-resourced
countries, although DTG is not yet available
and the timeline and procedures to obtain access
are not finalized. The long-acting formulation of
GSK1265744LA holds great promise for the
future of HIV prevention and treatment.
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